19 Results

People

  1. Hamilton
    Hamilton
  2. Zelenetz
    Zelenetz
  3. Noy
    Noy
  4. Palomba
    Palomba
  5. Batlevi
    Batlevi
  6. Matasar
    Matasar
  7. Kumar
    Kumar
  8. Horwitz
    Horwitz
  9. Caron
    Caron
  10. Moskowitz
    Moskowitz

Groups

  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. GSK Faculty (19)
  4. Hematologic Malignancies, Division of (19)
  5. Human Oncology and Pathogenesis Program (19)
  6. Lymphoma (19)
  7. Survivorship Research (19)
  8. Sloan Kettering Institute Postdocs (15)
  9. Epidemiology and Biostatistics (14)
  10. Population Sciences Research Program (14)
  1. "Center for Hematologic Malignancies"
  2. "GSK Faculty"
  3. "Andrew Zelenetz"
  4. "Audrey Hamilton"
Formats
  1. Meeting Abstract (15)
  2. Journal Article (3)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. GSK Faculty (19)
  4. Hematologic Malignancies, Division of (19)
  5. Human Oncology and Pathogenesis Program (19)
  6. Lymphoma (19)

More Groups

People
  1. Andrew Zelenetz (19)
  2. Audrey Hamilton (19)
  3. Ariela Noy (18)
  4. Maria Palomba (18)
  5. Connie Batlevi (17)
  6. Matthew Matasar (17)

More People

Years
  1. 2023 (2)
  2. 2022 (3)
  3. 2021 (4)
  4. 2020 (4)
  5. 2019 (2)
  6. 2017 (2)

More Years

Publications
  1. Blood (11)
  2. Journal of Clinical Oncology (3)
  3. Hematological Oncology (2)
  4. Blood Advances (1)
  5. Cancer Cell (1)
  6. The Lancet Haematology (1)
Publishers
  1. American Society of Hematology (12)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (2)
  4. Cell Press (1)
  5. Elsevier Science, Inc. (1)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of PET staging of follicular lymphoma on treatment outcomes and prognosis
    Meeting Abstract

    Alperovich, A.; Batlevi, C. L.; Intlekofer, A. M.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, M. L.; Moskowitz, A. J.; Gerecitano, J.; Hamlin, P. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Time from prognosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma
    Meeting Abstract

    Soumerai, J. D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K. S.; Palomba, M.; Gerecitano, J. F.; Noy, A.; Hamlin, P.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Outcomes of follicular lymphoma patients by dynamic FLIPI at diagnosis and initial treatment in the post-rituximab era
    Meeting Abstract

    Batlevi, C.; Alperovich, A.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Benchmark of progression free survival for multiple lines of therapy in follicular lymphoma treated in the rituximab era
    Meeting Abstract

    Alperovich, A.; Batlevi, C.; Smith, K.; Ying, Z.; Soumerai, J. D.; Copeland, A. R.; Joffe, E.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; more...
    Blood (2016)

    Fulltext@MSK | Save